HosseinBorghaeiDO

Oncology • Philadelphia, PA

Hematologic Oncology, Thoracic Cancer

Director, Thoracic Medical Oncology

Join to view full profile

Dr. Borghaei is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Borghaei's full profile

Already have an account?

Office
333 Cottman Ave
# Fox
Philadelphia, PA 19111
Phone+1 215-728-6900

Fax+1 215-728-3639

Summary

Dr. Hossein Borghaei is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Temple University Hospital and Fox Chase Cancer Center-American Oncologic Hospital. He received his medical degree from Philadelphia College of Osteopathic Medicine and has been in practice 21 years. He specializes in hematologic oncology and thoracic cancer and is experienced in immunotherapy, non-small cell lung cancer, urologic oncology, biomedical research, and combined modality therapy.

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Graduate HospitalResidency, Internal Medicine, 1997 - 2000
Philadelphia College of Osteopathic MedicineClass of 1996

Certifications & Licensure

PA State License 1997 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2007 Jul 05
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2011 Oct 20
Terminated
Phase 1, Phase 2
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
Completed
Phase 2
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
Completed
Phase 1
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer Start of enrollment: 2012 Aug 23
Completed
Not Applicable
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Start of enrollment: 2015 Mar 01
Terminated
Not Applicable
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Start of enrollment: 2017 Mar 29
Terminated
Phase 1, Phase 2
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Start of enrollment: 2020 Oct 08
Recruiting
Phase 2
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC Start of enrollment: 2022 Jul 13
Withdrawn
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.
David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry
Cancer Cell. 2024-12-09
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer.
Jaime Shaw, Xerxes Pundole, Akhila Balasubramanian, Erik S Anderson, Malaika Pastel
The Oncologist. 2024-12-06
Calls to action on lung cancer management and research.
May-Lucie Meyer, Fred R Hirsch, Paul A Bunn, Peter Ujhazy, David Fredrickson
The Oncologist. 2024-12-06

Press Mentions

Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
Warning on Use of Sotorasib After ICI in Lung CancerJune 1st, 2023
Pleural, Pericardial Effusion cfDNA Detects Actionable EGFR MutationsJanuary 19th, 2023
Join now to see all